MB-CART20.1 (Miltenyi Biotec)

N/A

Report date: 2024/05/17 20:00:39

Base Information

Drug NameMB-CART20.1 (Miltenyi Biotec)

Drug Alias NameAnti-CD20 CAR T cells - Miltenyi BiotecCD20-targeting CAR T Cells - Miltenyi Biotec

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionT lymphocyte replacementsAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsSkin Melanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMiltenyi Biotec

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMiltenyi Biomedicine Gmbh

Active IndicationsN/A

Inactive IndicationsSkin Melanoma

Other Information

ATC CodeN/A